Biopharmaceutical Research Company

Name

Biopharmaceutical Research Company

Legal name

BRC Therapeutics

Website

https://biopharmaresearchco.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

BRC Therapeutics is a clinical-stage biopharmaceutical company developing prescription cannabinoid-based medicines for chronic pain, with two investigational products in clinical trials for Complex Regional Pain Syndrome and aromatase inhibitor-induced arthralgia.

Ownership category

akta.pro rank

Product category

Cannabinoid Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)

Keywords

• Cannabinoid therapeutics
• Prescription drug development
• Clinical trial research
• Active pharmaceutical ingredients
• Pain management therapeutics

Headquarters

HQ city

Castroville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Prescription Pharmaceutical Products: The company is developing prescription cannabinoid-based medicines. Revenue will be generated through the sale of approved pharmaceutical products upon successful completion of clinical trials and regulatory approval. The company is currently pre-revenue with products in clinical development.

Go-to-market motion1 record

Marketing channels2 records

Core offering

Biopharmaceutical Research Company (BRC Therapeutics) develops prescription cannabinoid-based medicines for pain and other chronic conditions. The company operates cGMP manufacturing and is registered with the Drug Enforcement Administration. Two investigational products are currently in clinical trials: BRC-002 for Complex Regional Pain Syndrome (CRPS) with FDA IND clearance, and BRC-001 for Aromatase Inhibitor-Induced Arthralgia (AIIA).

Differentiator

Problem solved

Functional benefit

Products and services

• BRC-002

Quantifiable outcome

• Two investigational products in clinical trials for CRPS and AIIA

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Academic InstitutionscoreStrategic or Co-development PartnerBiopharmaceutical Research Company collaborates with academic institutions for research activities and the advancement of cannabinoid-based pharmaceutical ingredients.

Scale indicators3 records

Broad incumbents

• Jazz Pharmaceuticals: Jazz Pharmaceuticals acquired GW Pharmaceuticals in 2021, becoming the owner of Epidiolex - the first FDA-approved plant-derived cannabinoid prescription drug. As the established leader in prescription cannabinoid therapeutics, Jazz is the most relevant broad incumbent comparable to BRC.
• Tilray Brands: Tilray Brands operates one of the largest cannabis companies globally with a pharmaceutical division focused on medical cannabis and cannabinoid-based medicines. Its pharmaceutical operations and broader cannabis platform provide a broad-incumbent comparison to BRC.
• Canopy Growth: Canopy Growth is a major cannabis company with a medical division (Spectrum Therapeutics) developing cannabinoid-based medicines for therapeutic applications. Its scale and medical-pharma operations make it a relevant broad incumbent comparable to BRC.
• Cronos Group: Cronos Group is a global cannabinoid company with a pharmaceutical strategy developed through partnerships. Its pharmaceutical aspirations and scale make it a relevant broader incumbent comparable to BRC's pharmaceutical-grade cannabinoid focus.
• Aurora Cannabis: Aurora Cannabis operates one of the largest medical cannabis platforms globally, with focus on patient outcomes and clinical research. Its medical-cannabis infrastructure and clinical development efforts make it a comparable broad incumbent to BRC.

Direct peers

• InMed Pharmaceuticals: InMed Pharmaceuticals is a clinical-stage biopharmaceutical company developing cannabinoid-based therapeutics for diseases with high unmet medical need. Its prescription-focused pipeline approach directly parallels BRC's strategy.
• Corbus Pharmaceuticals: Corbus Pharmaceuticals was a leading cannabinoid-derived therapeutics developer (lenabasum) and remains a clinical-stage biopharmaceutical company focused on immuno-oncology and fibrosis. Its history in prescription cannabinoid development makes it directly comparable to BRC.
• Zynerba Pharmaceuticals: Zynerba Pharmaceuticals developed transdermal cannabinoid therapies (Zygel) for rare neurological and inflammatory conditions. Its clinical-stage cannabinoid drug development and proprietary delivery approach are closely comparable to BRC's prescription cannabinoid pipeline.
• Axim Biotechnologies: Axim Biotechnologies develops cannabinoid-based pharmaceutical therapeutics for multiple indications including pain and neurological conditions. Its prescription-focused cannabinoid drug pipeline directly parallels BRC's development approach.
• GB Sciences: GB Sciences is a biopharmaceutical company developing cannabinoid-based prescription medicines for complex disease states. Its focus on pharmaceutical-grade cannabinoid formulations for chronic conditions is closely comparable to BRC.

Market position

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biopharmaceutical Research Company